Investors & Media

The investor relations section of Selvita S.A. is addressed to all capital market participants and media, and in particular to our shareholders, analysts, individual and institutional investors interested in our company.

You’ll be able to find here the latest information on our financial results, current operations and development plans, as well as a range of other useful information. If there is anything more you should need, don’t hesitate to contact us!

Investors & Media

Overview

Selvita share price [PLN]

News feed

Selvita Q3 2019 results: accelerated growth, 45 percent increase in commercial revenues and strong long-term outlook
07 November 2019

Selvita Q3 2019 results: accelerated growth, 45 percent increase in commercial revenues and strong long-term outlook

Continue reading
Selvita to Exhibit at the 9th Drug Discovery Innovation Programme
21 October 2019

Selvita to Exhibit at the 9th Drug Discovery Innovation Programme

Continue reading
Selvita and Ryvu Therapeutics Announce Independent Trading<br/> on the Warsaw Stock Exchange
16 October 2019

Selvita and Ryvu Therapeutics Announce Independent Trading
on the Warsaw Stock Exchange

Continue reading

Reports

Show
  • 07 November 2019

    Raport ESPI SA-Q 3/2019

    Selvita S.A. Quarterly Report 2019 Q3 (Summary)

Shareholder structure

Share in capital
Share in votes
Shareholder Share in capital Share in votes
Paweł Przewięźlikowski
Bogusław Sieczkowski
Augebit FIZ*
Nationale Nederlanden OFE
Remaining Management Board and Supervisory Board Members
Remaining Shareholders
* the beneficiary of Augebit FIZ is Tadeusz Wesołowski – Vice Chairman of Selvita Supervisory Board; information based on the number of shares from the last notification provided by the shareholder to the Company (without taking into account the dilution resulting from the issue of H shares).
selvita_logo

Contacts